Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications

Cell Stress and Chaperones

Volumn 10, Issue 2, 2005, Pages 86-103

  Ciocca, Daniel R ^a   Calderwood, Stuart K ^b,c  

^a INSTITUTO ARGENTINO DE NIVOLOGÍA   (Argentina)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; CHAPERONE; CYCLIN D1; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; GLYCOPROTEIN P; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 10; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 78; HEAT SHOCK PROTEIN 90; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROGESTERONE RECEPTOR; PROTEIN P53; UNCLASSIFIED DRUG;

BLADDER CANCER; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RESEARCH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; ENDOMETRIUM CARCINOMA; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LIVER CARCINOMA; MALIGNANT FIBROUS HISTIOCYTOMA; MELANOMA; METASTASIS; MOUTH CANCER; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SHORT SURVEY; STOMACH CARCINOMA; UTERINE CERVIX CARCINOMA; UTERUS CARCINOMA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HEAT-SHOCK PROTEINS; HUMANS; IMMUNE SYSTEM; NEOPLASMS; PROGNOSIS;

EID: 21744445069     PISSN: 13558145     EISSN: None     Source Type: Journal    
DOI: 10.1379/CSC-99r.1     Document Type: Short Survey

References (231)

1. Abe M, Manola JB, Oh WK, Parslow DL, George DJ, Austin CL, Kantoff PW. 2004. Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. Clin Prostate Cancer 3: 49-53.
2. Abd el All H, Rey A, Duvillard P. 1998. Expression of heat shock protein 70 and c-myc in cervical carcinoma. Anticancer Res 18: 1533-1536.
3. Arnold-Schild D, Hanau D, Spehner D, Schmid C, Rammensee HG, de la Salle H, Schild H. 1999. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol 162: 3757-3760.
4. Arrigo A-P, Paul C, Duchase C, et al. 2002. Small stress proteins: novel negative modulators of apoptosis induced independently of reactive oxygen species. Prog Mol Subcell Biol 28: 185-204.
5. Arts HJ, Hollema H, Lemstra W, Willemse PH, De Vries EG, Kampinga HH, Van der Zee AG. 1999. Heat-shock-protein-27 (Hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. Int J Cancer 84: 234-238.
6. Assikis VJ, Daliani D, Pagliaro L, et al. 2003. Phase II study of an autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC). Proc ASCO 22: 386 (A1552).
7. Assimakopoulou M. 2000. Human meningiomas: immunohistochemical localization of progesterone receptor and heat shock protein 27 in absence of estrogen receptor and PS2. Cancer Detect Prev 24: 163-168.
8. Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, Varakis I. 1997. Prognostic significance of Hsp27 in astrocytic brain tumors: an immunohistochemical study. Anticancer Res 17: 2677-2682.
9. Assimakopoulou M, Varakis J. 2001. AP-1 and heat shock protein 27 expression in human astrocytomas. J Cancer Res Clin Oncol 127: 727-732.
10. Athanassiadou P, Petrakakou E, Sakelariou V, Zerva C, Liossi A, Michalas S, Athanassiades P. 1998. Expression of p53, bcl-2 and heat shock protein (Hsp72) in malignant and benign ovarian tumors. Eur J Cancer Prev 7: 225-231.
11. Banerji U, O'Donnell A, Scurr M, et al. 2003. A pharmacokinetically (PK)-pharmacodynamically (PD) guided phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino, 17-demethoxy-geldanamycin (17AAG). Proc ASCO 22: 199 (A797).
12. Barril X, Davis B, Collier A, et al. 2003. Structure-based drug discovery based an a novel inhibitor of the Hsp90 molecular chaperone. Proc AACR 44: 796 (A3488).
13. Bayerl C, Dorfner B, Rzany B, Fuhrmann E, Coelho CC, Jung EG. 1999. Heat shock protein HSP27 is expressed in all types of basal cell carcinoma in low and high risk UV exposure groups. Eur J Dermatol 9: 281-284.
14. Beckmann RP, Mizzen LA, Welch WJ. 1990. Interaction of HSP70 with newly synthesized proteins; implications for protein folding and assembly. Science 248: 850-854.
15. Belli F, Testori A, Rivoltini L, et al. 2002. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunological findings. J Clin Oncol 20: 4169-4180.
16. Blagosklonny MV 2001. Re: Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 93: 239-240.
17. Blagosklonny MV, Toretsky J, Bohen S, Neckers L. 1996. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci U S A 93: 8379-8383.
18. Bonay M, Soler P, Riquet M, Battesti JP, Hance AJ, Tazi A. 1994. Expression of heat shock proteins in human lung and lung cancers. Am J Respir Cell Mol Biol 10: 453-461.
19. Bostwick DG. 2000. Immunohistochemical changes in prostate cancer after androgen deprivation therapy. Mol Urol 4: 101-106.
20. Bubendorf L, Kolmer M, Kononen J, et al. 1999. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 91: 1758-1764.
21. Buchner J. 1999. HSP 90 & Co. - a holding for folding. Trends Biochem Sci 24: 136-142.
22. Cappello F, Bellafiore M, David S, Anzalone R, Zummo G. 2003a. Ten kilodalton heat shock protein (HSP10) is overexpressed during carcinogenesis of large bowel and uterine cervix. Cancer Lett 196: 35-41.
23. Cappello F, Bellafiore M, Palma A, et al. 2003b. 60 KDa chaperonin (HSP60) is over-expressed during colorectal carcinogenesis. Eur J Histochem 47: 105-110.
24. Cappello F, Bellafiore M, Palma A, et al. 2002-2003. Expression of 60-kD heat shock protein increases during carcinogenesis in the uterine exocervix. Pathobiology 70: 83-88.
25. Cappello F, Rappa F, David S, Anzalone R, Zummo G. 2003c. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis. Anticancer Res 23: 1325-1331.
26. Cardillo MR, Sale P, Di Silverio F. 2000. Heat shock protein-90, IL-6 and IL-10 in bladder cancer. Anticancer Res 20: 4579-4583.
27. Castelli C, Rivoltini L, Rini F, et al. 2004. Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother 53: 227-233.
28. Chant ID, Rose PE, Morris AG. 1995. Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry. Br J Haematol 90: 163-168.
29. Chauhan D, Li G, Auclair D, Hideshima T, et al. 2003. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood 101: 3606-3614.
30. Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N. 2001. A small molecule designed to bind to the adenine nucleotide pocked of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 8: 289-299.
31. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA. 2000. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumor by administration of fusion protein comprising mycobacterium bovis bacille Calmette-Guerin (BCG) Hsp65 and HPV16 E7. Clin Exp Immunol 121: 216-225.
32. Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, Hirohashi S. 2003. Expression profiling in multistage hepatocarcionogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 37: 198-207.
33. Ciocca DR, Clark GM, Tandon AK, Fuqua SAW, Welch WJ, McGuire WL. 1993. Heath shock protein Hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst 85: 570-574.
34. Ciocca DR, Green S, Elledge RM, et al. 1998. Heat shock proteins Hsp27 and Hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group study). Clin Cancer Res 5: 1263-1266.
35. Ciocca DR, Jorge AD, Jorge O, et al. 1991. Estrogen receptors, progesterone receptors and heat-shock 27-kD protein in liver biopsy specimens from patients with hepatitis B virus infection. Hepatology 13: 838-844.
36. Ciocca DR, Lo Castro G, Alonio V, Cobo MF, Lotfi H, Teyssié A. 1992. Effect of human papillomavirus infection on estrogen receptor and heat shock protein Hsp27 phenotype in human cervix and vagina. Int J Gynecol Pathol 11: 113-121.
37. Ciocca DR, Puy LA, Edwards DP, Adams DJ, McGuire WL. 1985. The presence of an estrogen-regulated protein detected by monoclonal antibody in abnormal human endometrium. J Clin Endocrinol Metab 60: 137-143.
38. Ciocca DR, Puy LA, Fasoli LC. 1989. Study of estrogen receptor, progesterone receptor, and the estrogen-regulated Mr 24,000 protein in patients with carcinomas of the endometrium and cerviz. Cancer Res 49: 4298-4304.
39. Ciocca DR, Puy LA, Lo Castro G. 1986. Localization of an estrogen-responsive protein in the human cervix during menstrual cycle, pregnancy, and menopause and in abnormal cervical epithelia without atypia. Am J Obstet Gynecol 155: 1090-1096.
40. Ciocca DR, Rozados VR, Cuello-Carrión FD, Gervasoni SI, Matar P, Scharovsky OG. 2003. Heat shock proteins 25 and 70 in rodent tumors treated with doxorubicin and lovastatin. Cell Stress Chaperones 8: 26-36.
41. Ciocca DR, Stati AO, Amprino de Castro MM. 1990. Colocalization of estrogen and progesterone receptors with an estrogen-regulated heat shock protein in paraffin sections of human breast and endometrial cancer tissue. Breast Cancer Res Treat 16: 243-251.
42. Ciupitu AMT, Petersson M, Kono K, Charo J, Kiesslin R. 2002. Immunization with heat shock protein 70 from methylcholanthrene-induced sarcomas induces tumor protection correlating with in vitro T cell response. Cancer Immunol Immunother 51: 163-170.
43. Conroy SE, Sasieni PD, Amin V, Wang DY, Smith P, Fentiman IS, Latchman DS. 1998a. Antibodies to heat-shock protein 27 are associated with improved survival in patients with breast cancer. Br J Cancer 77: 1875-1879.
44. Conroy SE, Sasieni PD, Fentiman I, Latchman DS. 1998b. Autoantibodies to the 90kDa heat shock protein and poor survival in breast cancer patients. Eur J Cancer 34: 942-943.
45. Cornford PA, Dodson AR, Parsons KF, et al. 2000. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60: 7099-7105.
46. Damstrup L, Andersen J, Kufe DW, Hayes DF, Skovgaard Poulsen H. 1992. Immunocytochemical determination of the estrogen-regulated proteins Mr 24,000, Mr 52,000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptor. Ann Oncol 3: 71-77.
47. Daniels GA, Sanchez-Perez L, Diaz RM, et al. 2004. A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol 22: 1125-1132.
48. Delhaye M, Gulbis B, Galand P, Mairesse N. 1992. Expression of 27-kD heat shock protein isoforms in human neoplastic and non-neoplastic liver tissues. Hepatology 16: 382-389.
49. Dressler LG, Ramzy I, Sledge GW, McGuire WL. 1986. A new marker of maturation in the cervix: the estrogen-regulated 24K protein. Obstet Gynecol 68: 825-831.
50. Dundas SR, Lawrie LC, Rooney PH, Murray GI. 2005. Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J Pathol 205: 74-81.
51. Efferth T, Schulten HG, Thelen P, et al. 2001. Differential expression of the heat shock protein 70 in the histological compartments of nephroblastomas. Anticancer Res 21: 2915-2920.
52. Elledge RM, Clark GM, Fuqua SAW, Yo YY, Allred DC. 1994. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 54: 3752-3757.
53. Elpek GO, Karaveli S, Simsek T, Keles N, Aksoy NH. 2003. Expression of heat-shock proteins Hsp27, Hsp70 and Hsp90 in malignant epithelial tumor of the ovaries. APMIS 111: 523-530.
54. Erkizan O, Kirkali G, Yorukoglu K, Kirkali Z. 2004. Significance of heat shock protein-27 expression in patients with renal cell carcinoma. Urology 64: 474-478.
55. Fanelli MA, Cuello Carrion FD, Dekker J, Schoemaker J, Ciocca DR. 1998. Serological detection of heat shock protein Hsp27 in normal and breast cancer patients. Cancer Epidemiol Biomarkers Prev 7: 791-795.
56. Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. 2003. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood 101: 245-252.
57. Fernandez PM, Tabbara SO, Jacobs LK, Manning FC, Tsangaris TN, Schwartz AM, Kennedy KA, Patierno SR. 2000. Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res Treat 59:15-26.
58. Fortin A, Raybaud-Diagene H, Tetu B, Deschenes R, Huot J, Landry J. 2000. Overexpression of the 27 KDa heat shock protein is associated with thermoresistance and chemoresistance but not with radioresistance. Int J Radiat Oncol Biol Phys 46: 1259-1266.
59. Freeman BC, Yamamoto KR. 2002. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 296: 2232-2235.
60. Gago FE, Tello OM, Diblasi AM, Ciocca DR. 1998. Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients. J Steroid Biochem Mol Biol 67: 431-437.
61. Gandour-Edwards R, Kapadia SB, Janecka IP, Martinez AJ, Barnes L. 1995. Biologic markers of invasive pituitary adenomas involving the sphenoid sinus. Modern Pathol 8: 160-164.
62. Gandour-Edwards R, Trock BJ, Gumerlock P, Donald PJ. 1998. Heat shock protein and p53 expression in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 118: 610-615.
63. Geisler JP, Geisler HE, Tammela J, Miller GA, Weimann MC, Zhou Z. 1999. A study of heat shock protein 27 in endometrial carcinoma. Gynecol Oncol 72: 347-350.
64. Geisler JP, Geisler HE, Tammela J, Wiemann MC, Zhou Z, Miller GA, Crabtree W. 1998. Heat shock protein 27: an independent prognostic indicator of survival in patients with epithelial ovarian carcinoma. Gynecol Oncol 69: 14-16.
65. Georgopolis C, Welch WJ. 1993. Role of the major heat shock proteins as molecular chaperones. Ann Rev Cell Biol 9: 601-634.
66. Germain I, Tetu B, Brisson J, Mondor M, Cherian MG. 1996. Markers of chemoresistance in ovarian carcinomas: an immunohistochemical study of 86 cases. Int J Gynecol Pathol 15: 54-62.
67. Gething MJ, Sambrook J. 1992. Protein folding in the cell. Nature 355: 33-45.
68. Gyrd-Hansen M, Nylandsted J, Jaattela M. 2004. Heat shock protein 70 promotes cancer cell viability by safeguarding lysosomal integrity. Cell Cycle, 3: 1484-1485.
69. Hahn WC, Weinberg RA. 2002. Rules for making human tumor cells. N Engl J Med 347: 1593-1603.
70. Harrison JD, Jones JA, Ellis IO, Morris DL. 1991. Oestrogen receptor D5 antibody is an independent negative prognostic factor in gastric cancer. Br J Surg 78: 334-336.
71. Heike M, Frenzel C, Meier D, Galle PR. 2000. Expression of stress protein gp96, a tumor rejection antigen, in human colorectal cancer. Int J Cancer 86: 489-493.
72. Henics T, Nagy E, Oh HJ, Csermely P, von Gabain A, Subjeck JR. 1999. Mammalian HSP70 and HSP110 proteins bind to RNA motifs involved in mRNA stability. J Biol Chem 274: 17318-17324.
73. Hermisson M, Strik H, Rieger J, Dichgans J, Meyermann R, Weller M. 2000. Expression and functional activity of heat shock proteins in human glioblastoma multiforme. Neurology 54: 1357-1365.
74. Hickey E, Weber LA. 1982. Preferential translation of heat shock mRNAs in HeLa cells. In: Heat Shock; from Bacteria to Man, ed Schlesinger M, Ashburner M, Tissieres A. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 199-206.
75. Hightower LE. 1991. Heat shock, stress proteins, chaperones and proteotoxicity. Cell 66: 191-197.
76. Hitotsumatsu T, Iwaki T, Fukui M, Tateishi J. 1996. Distinctive immunohistochemical profiles of small heat shock proteins (heat shock protein 27 and alpha B-Crystallin) in human brain tumors. Cancer 77: 352-361.
77. Hoang AT, Huang J, Rudra-Ganguly N, Zheng J, Powell WC, Rabindran SK, Wu C, Roy-Burman P. 2000. A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma. Am J Pathol 156: 857-864.
78. Hsu PL, Hsu SM. 1998. Abundance of heat shock proteins (Hsp89, Hsp60, and Hsp27) in malignant cells of Hodgkin's disease. Cancer Res 58: 5507-5513.
79. Hwang TK, Han HS, Choi HK, Lee YJ, Kim YJ, Han MY, Park YM. 2003. Differential, stage-dependent expression of Hsp70, Hsp 110, and Bcl-2 in colorectal cancer. J Gastroenterol Hepatol 18: 690-700.
80. Ito T, Kawabe R, Kurasono Y, Hara M, Kitamura H, Fujita K, Kanisawa M. 1998. Expression of heat shock proteins in squamous cell carcinoma of the tongue: an immunohistochemical study. J Oral Pathol Med 27: 18-22.
81. Iwaya K, Tsuda H, Fujita S, Suzuki M, Hirohashi S. 1995. Natural state of mutant p53 protein and heat shock protein 70 in breast cancer tissues. Lab Invest 72: 707-714.
82. Jalbout M, Bouaouina N, Gargouri J, Corbex M, Ben Ahmed S, Chouchane L. 2003. Polymorphism of the stress protein HSP70-2 gene is associated with the susceptibility to the nasopharyngeal carcinoma. Cancer Lett 193: 75-81.
83. Jameel A, Skilton RA, Cambell TA, Chander SK, Coombes RC, Luqmani YA. 1992. Clinical and biological significance of HSP89 alpha in human breast cancer. Int J Cancer 50: 409-415.
84. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. 2000. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 88: 232-238.
85. Jones EL, Zhao MJ, Stevenson MA, Calderwood SK. 2004. The 70 kilodalton heat shock protein is an inhibitor of apoptosis in cancer. Int J Hyperthermia 20: 835-849.
86. Kamishima T, Fukuda T, Usuda H, Takato H, Iwamoto H, Kaneko H. 1997. Carcinosarcoma of the urinary bladder: expression of epithelial markers and different expression of heat shock proteins between epithelial and sarcomatous elements. Pathol Int 47: 166-173.
87. Kanitakis J, Zambruno G, Viac J, Tommaselli L, Thivolet J. 1989. Expression of an estrogen receptor-associated protein (p29) in epithelial tumors of the skin. J Cutan Pathol 16: 272-276.
88. Kapranos N, Kominea A, Konstantinopoulos PA, Savva S, Artelaris S, Vandoros G, Sotiropoulou-Bonikou G, Papavassiliou AG. 2002. Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol 128: 426-432.
89. Kasimir-Bauer S, Beelen DW, Flasshove M, Noppeney R, Seeber S, Scheulen ME. 2002. Impact of the expression of P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction chemotherapy and long-term survival in patients with de novo acute myeloid leukemia. Exp Hematol 30: 1302-1308.
90. Kasimir-Bauer S, Ottinger H, Meusers P, Beelen DW, Brittinger G, Seeber S, Scheulen ME. 1998. In acute myeloid leukaemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27, is predictive of the response to induction chemotherapy. Exp Hematol 26: 1111-1117.
91. Kassem HSh, Sangar V, Cowan R, Clarke N, Margison GP. 2002. A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder carcinoma. Int J Cancer 101: 454-460.
92. Kato M, Herz F, Hirano A. 1992. Expression of stress-response (heat-shock) protein 27 in human brain tumors: an immunohistochemical study. Acta Neuropathol 83: 420-422.
93. Kato S, Kato M, Hirano A, Takikawa M, Ohama E. 2001. The immunohistochemical expression of stress-response protein (srp) 60 in human brain tumors: relationship of srp 60 to the other five srps, proliferating cell nuclear antigen and p53 protein. Histol Histopathol 16: 809-820.
94. Kaur J, Das SN, Srivastava A, Ralhan R. 1998. Cell surface expression of 70 kDa heat shock protein in human oral dysplasia and squamous cell carcinoma: correlation with clinicopathological features. Oral Oncol 34: 93-98.
95. Kawanishi K, Shiozaki H, Doki Y, et al. 1999. Prognostic significance of heat shock proteins 27 and 70 in patients with squamous cell carcinoma of the esophagus. Cancer 85: 1649-1657.
96. Keeling J, McKee GT. 1999. Heat shock protein (HSP)27: a further refinement in the diagnosis of suspicious fine needle aspirates of breast. Cytopathology 10: 40-49.
97. Khalid H, Tsutsumi K, Yamashita H, Kishikawa M, Yasunaga A, Shibata S. 1995. Expression of the small heat shock protein (Hsp) 27 in human astrocytomas correlates with histologic grades and tumor growth fractions. Cell Mol Neurobiol 15: 257-268.
98. Kim KK, Jang TJ, Kim JR. 1998. HSP70 and ER expression in cervical intraepithelial neoplasia and cervical cancer. J Korean Med Sci 13: 383-388.
99. Kimura E, Enns RE, Alcaraz JE, Arboleda J, Slamon DJ, Howell SB. 1993. Correlation of the survival of ovarian cancer patients with mRNA expresion of the 60-kD heat-shock protein HSP-60. J Clin Oncol 11: 891-898.
100. King KL, Li AF, Chau GY, Chi CW, Wu CW, Huang CL, Lui WY. 2000. Prognostic significance of heat shock protein-27 expression in hepatocellular carcinoma and its relation to histologic grading and survival. Cancer 88: 2464-2470.
101. Konstadoulakis MM, Vezeridis M, Hatziyianni E, Karakousis CP, Cole B, Bland KI, Wanebo HJ. 1998. Molecular oncogene markers and their significance in cutaneous malignant melanoma. Ann Surg Oncol 5: 253-260.
102. Kontogeorgos G, Kapranos N, Thodou E, Sambaziotis D, Tsagarakis S. 1999. Immunocytochemical accumulation of p53 in corticotroph adenomas: relationship with heat shock proteins and apoptosis. Pituitary 1: 207-212.
103. Korneeva I, Bongiovanni AM, Girotra M, Caputo TA, Witkin SS. 2000. Serum antibodies to the 27-kd heat shock protein in women with gynaecologic cancers. Am J Obstet Gynecol 183: 18-21.
104. Kumamoto H, Suzuki T, Ooya K. 2002. Immunohistochemical analysis of inducible nitric oxide synthetase (iNOS) and heat shock proteins (HSPs) in ameloblastomas. J Oral Pathol Med 31: 605-611.
105. Lambot MA, Peny MO, Fayt I, Haot J, Noel JC. 2000. Overexpression of 27-kDa heat shock protein relates to poor histological differentiation in human oesophageal squamous cell carcinoma. Histopathology 36: 326-330.
106. Landry J, Bernier D, Chretien P, Nicole LM, Tanguay RM, Marceau N. 1982. Synthesis and degradation of heat shock proteins during the development and decay of thermotolerance. Cancer Res 42: 2457-2461.
107. Langdon SP, Rabiasz GJ, Hirst GL, King RJ, Hawkins RA, Smyth JF, Miller WR. 1995. Expression of the heat shock protein HSP27 in human ovarian cancer. Clin Cancer Res 1: 1603-1609.
108. Lazaris AC, Theodoropoulos GE, Aroni K, Saetta A, Davaris PS. 1995. Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma. Virchows Arch 426: 461-467.
109. Lazaris ACh, Chatzigianni EB, Panoussopoulos D, Tzimas GN, Davaris PS, Golematis BCh. 1997. Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified. Breast Cancer Res Treat 43: 43-51.
110. Lee AS, Dong D, Reddy R, Mao C, Gomer C, Gambhir S, Bading J. 2003. Stress induction of the glucose regulated protein (GRP78): applications in cancer therapy. Proc Int Cong Stress Responses Biol Med 1: 27.
111. Lee MO, Kim EO, Kwon HJ, Kim YM, Kang HJ, Kang H, Lee JE. 2002. Radicicol represses the transcriptional function of the estrogen receptor by suppressing the stabilization of the receptor by heat shock protein 90. Mol Cell Endocrinol 188: 47-54.
112. Lehmann TA, Bennet WP, Metcalf RA. 1991. P53 mutations, ras mutations and p53-heat shock protein complexes in human lung carcinoma cell lines. Cancer Res 51: 4090-4096.
113. Lemoisson E, Cren H, Goussard J. 1994. Chromatographic separation of eight progesterone receptor isoforms in human breast tumors, and detection by radioligand and monoclonal antibodies. Association with Hsp90 and Hsp70 heat shock proteins. Ann Biol Clin 52: 433-442.
114. Leonardi R, Pannone G, Magro G, Kudo Y, Takata T, Lo Muzio L. 2002. Differential expression of heat shock protein 27 in normal oral mucosa, oral epithelial dysplasia and squamous cell carcinoma. Oncol Rep 9: 61-266.
115. Li GC, Werb Z. 1982. Correlation between the synthesis of heat shock proteins and the development of thermotolerance in CHO fibroblasts. Proc Natl Acad Sci USA 79: 3218-3222.
116. Lindquist S, Craig EA. 1988. The heat shock proteins. Ann Rev Genet 22: 631-637.
117. Liu FF, Miller N, Levin W, et al. 1996. The potential role of HSP70 as an indicator of response to radiation and hyperthermia treatments for recurrent breast cancer. Int J Hypertherm 12: 197-208.
118. Liu X, Ye L, Wang J, Fan D. 1999. Expression of heat shock protein 90 beta in human gastric cancer tissue and SGD7901/VCR of MDR-type gastric cancer cell line. Chin Med J (Engl) 112: 1133-1137.
119. Love S, King RJB. 1994. A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer 69: 743-748.
120. Luo LY, Herrera I, Soosaipillai A, Diamandis EP. 2002. Identification of heat shock protein 90 and other proteins as antigens by serological screening of an ovarian carcinoma expression library. Br J Cancer 87: 339-343.
121. Maehara Y, Oki E, Abe T, Tokunaga E, Shibahara K, Kakeji Y, Sugimachi K. 2000. Overexpression of the heat shock protein HSP70 family and p53 protein and prognosis for patients with gastric cancer. Oncology 58: 144-151.
122. Maitra A, Iacobuzio-Donahue C, Rahman A, et al. 2002. Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47. Am J Clin Pathol 118: 52-59.
123. Malusecka E, Zborek A, Krzyzowska-Gruca S, Krawczyk Z. 2001. Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas. An immunohistochemical study. Anticancer Res 21: 1015-1021.
124. Manjili MH, Henderson R, Chen X, Repasky E, Subjeck JR. 2003. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. Proc AACR 44: 458 (A2009).
125. Manjili MH, Henderson R, Wang XY, Chen X, Li Y, Repasky E, Kazim L, Subjeck JR. 2002. Development of a recombinant HSPllO-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res 62: 1737-1742.
126. Mazzaferro V, Coppa J, Carrabba MG, et al. 2003. Vaccination with autologous tumor-derived heat shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 9: 3235-3245.
127. McMillan DR, Xiao X, Shao L, Graves K, Benjamin IJ. 1998. Targeted disruption of heat shock transcription factor 1 abolishes thermotolerance and protection against heat-inducible apoptosis. J Biol Chem 273: 7523-7528.
128. Mendez F, Sandigursky M, Kureekattil RP, Kenny MK, Franklin WA, Bases R. 2003. Specific stimulation of human apurinic/apyrimidinic endonuclease by heat shock protein 70. DNA Repair 2: 259-271.
129. Mese H, Sasaki A, Nakayama S, Yoshioka N, Yoshihama Y, Kishimoto K, Matsumura T. 2002. Prognostic significance of heat shock protein 27 (HSP27) in patients with oral squamous cell carcinoma. Oncol Rep 9: 341-344.
130. Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remani S, Chouchane L. 2001. Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein Hsp702: susceptibility and prognostic implications in breast carcinoma. Cancer 91: 672-678.
131. Michils A, Redivo M, Zegers de Beyl V, de Maertelaer V, Jacobovitz D, Rocmans P, Duchateau J. 2001. Increased expression of high but not low molecular weight heat shock proteins in resectable lung carcinoma. Lung Cancer 33: 59-67.
132. Mileo AM, Fanuele M, Battaglia F, Scambia G, Benedetti-Panici P, Mancuso S, Ferrini U. 1990. Selective over-expression of mRNA coding for 90 KDa stress-protein in human ovarian cancer. Anticancer Res 10: 903-906.
133. Missotten GS, Journee-de Korver JG, de Wolff-Rouendaal D, Keunen JE, Schlingemann RO, Jager MJ. 2003. Heat shock protein expression in the eye and in uveal melanoma. Invest Ophtalmol Vis Sci 44: 3059-3065.
134. Mitsiades N, Mitsiades CS, Poulaki V, et al. 2002. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 99: 14374-14379.
135. Muñoz de Toro MM, Luque EH. 1997. Lack of relationship between the expresion of Hsp27 heat shock estrogen receptor-associated protein and estrogen receptor or progestrone receptor status in male breast carcinoma. J Steroid Biochem Mol Biol 60: 277-284.
136. Nadin S, Vargas-Roig LM, Cuello-Carrión FD, Ciocca DR. 2003. Deoxyribonucleic acid damage induced by doxorubicin in peripheral blood mononuclear cells: possible roles for the stress response and the deoxyribonucleic acid repair process: Cell Stress Chaperones 8: 361-371.
137. Nanbu K, Konishi I, Komatsu T, Mandai M, Yamamoto S, Kuroda H, Koshiyama M, Mori T. 1996. Expression of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Correlation with clinicopathology, sex steroid receptor status, and p53 protein expression. Cancer 77: 330-338.
138. Nanbu K, Konishi I, Mandai M, Kuroda H, Hamid AA, Komatsu T, Mori T. 1998. Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Cancer Detect Prev 22: 549-555.
139. Nakai A, Tanabe M, Kawazoe Y, Inazawa J, Morimoto RI, Nagata K. 1997. HSF4, a new member of the human heat shock factor family which lacks properties of a transcriptional activator. Mol Cell Biol 17: 469-481.
140. Nakajima M, Kuwano H, Miyazaki T, Masuda N, Kato H. 2002. Significant correlation between expression of heat shock proteins 27, 70 and lymphocyte infiltration in esophageal squamous cell carcinoma. Cancer Lett 178: 99-106.
141. Navarro D, Cabrera JJ, Leon L, et al. 1992. Endometrial stromal sarcoma expression of estrogen receptors, progesterone receptors and estrogen-induced srp27 (24K) suggests hormone responsiveness. J Steroid Biochem Mol Biol 41: 589-596.
142. Neckers L, Ivy SP. 2003. Heat shock protein 90. Curr Opin Oncol 15: 419-424.
143. Netzer WF, Hartl FU 1998. Protein folding in the cytosol: chaperonin-dependent and-independent mechanisms. Trends Biochem Sci 23: 68-74.
144. Noessner E, Gastpar R, Milani V, et al. 2002. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 169: 5424-5432.
145. Noguchi T, Takeno S, Shibata T, Uchida Y, Yokoyama S, Muller W. 2002. Expression of heat shock protein 70 in grossly resected esophageal squamous cell carcinoma. Ann Thorac Surg 74: 222-226.
146. Numoto RT. 1994. Pineal parenchyma! tumors: cell differentiation and prognosis. J Cancer Res Clin Oncol 120: 683-690.
147. Nylandsted J, Brand K, Jaattela M. 2000a. Heat shock protein 70 is required for the survival of cancer cells. Ann N Y Acad Sci 926: 122-125.
148. Nylandsted J, Rohde M, Brand K, Bastholm L, Elling F, Jaattela M. 200Ob. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc Natl Acad Sci U S A 97: 7871-7876.
149. Nylandsted J, Wick W, Hirt UA, Brand K, Rohde M, Leist M, Weller M, Jaattela M. 2002. Eradication of glioblastoma, and breast and colon carcinoma xenografts by Hsp70 depletion. Cancer Res 62: 7139-7142.
150. Osterreich S, Hilsenbeck SG, Ciocca DR, Allred DC, Clark GM, Chamness GC, Osborne CK, Fuqua SA. 1996. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res 2: 1199-1206.
151. Ogata M, Naito Z, Tanaka S, Moriyama Y, Asano G. 2000. Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J Nippon Med Sch 67: 177-185.
152. Park CS, Joo IS, Song SY, Kim DS, Bae DS, Lee JH. 1999. An immunohistochemical analysis of heat shock protein 70, p53, and estrogen receptor status in carcinoma of the uterine cervix. Gynecol Oncol 74: 53-60.
153. Pignatelli D, Ferreira J, Soares P, Costa MJ, Magalhaes MC. 2003. Immunohistochemical study of heat shock proteins 27, 60 and 70 in the normal human adrenal and in adrenal tumors with suppressed ACTH production. Microsc Res Tech 61: 315-323.
154. Finder SE, Balsitis M, Ellis IO, Landon M, Mayer RJ, Lowe J. 1994. The expression of alpha B-crystallin in epithelial tumors: a useful tumor marker? J Pathol 174: 209-215.
155. Piura B, Rabinovich A, Yavelsky V, Wolfson M. 2002. Heat shock proteins and malignancies of the female genital tract. Harefuali 141: 962-972, 1010, 1009.
156. Pratt WB, Toft DO. 2003. Regulation of signalling protein function and trafficking by the Hsp90/Hsp70-based chaperone machinery. Exp Biol Med 228: 111-133.
157. Puy LA, Lo Castro G, Olcese JE, Lotfi HO, Brandi HR, Ciocca DR. 1989. Analysis of a 24-kilodalton (KD) protein in the human uterine cervix during abnormal growth. Cancer 64: 1067-1973.
158. Rabindran SK, Gioorgi G, Clos J, Wu C. 1991. Molecular cloning and expression of a human heat shock factor, HSF1. Proc Natl Acad Sci U S A 88: 6906-6910.
159. Ralhan R, Kaur J. 1995. Differential expression of Mr 70,000 heat shock protein in normal, premalignant, and malignant human uterine cervix. Clin Cancer Res 1: 1217-1222.
160. Rau B, Gaestel M, Wust P, Stahl J, Mansmann U, Schlag PM, Benndorf R. 1999. Preoperative treatment of rectal cancer with radiation, chemotherapy and hyperthermia: analysis of treatment efficacy and heat shock response. Radiat Res 151: 479-488.
161. Ricaniadis N, Kataki A, Agnantis N, Androulakis G, Karakousis CP. 2001. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma. Eur J Surg Oncol 27: 88-93.
162. Rivoltini L, Castelli C, Carrabba M, et al. 2003. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol 171: 3467-3474.
163. Rocchi P, Signaevsky M, Beraldi E, Nelson C, Cleave M. 2003. Heat shock protein 27 expression increases in prostate cancer cells after androgen ablation and plays cytoprotective role during androgen-independent progression. Proc AACR 44: 1279 (A5581).
164. Rocchi P, So A, Kojima S, et al. 2004. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64: 6595-6602.
165. Sagol O, Tuna B, Coker A, et al. 2002. Immunohistochemical detection of pS2 protein and heat shock protein-70 in pancreatic adenocarcinomas. Relationship with disease extend and patient survival. Pathol Res Pract 198: 77-84.
166. Santarosa M, Favaro D, Quaia M, Galligioni E. 1997. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Enr J Cancer 33: 873-877.
167. Schneider J, Jimenez E, Marenbach K, Marx D, Meden H. 1998. Co-expression of the MDR1 gene and HSP27 in human ovarian cancer. Anticancer Res 18: 2967-2971.
168. Schneider J, Jimenez E, Marenbach K, Romero H, Marx D, Meden H. 1999. Immunohistochemical detection of HSP60-expression in human ovarian cancer. Correlation with survival in a series of 247 patients. Anticancer Res 19: 2141-2146.
169. Schuetz TJ, Gallo GJ, Sheldon L, Tempst P, Kingston RE. 1991. Isolation of a cDNA for HSF2; evidence for two heat shock factors in humans. Proc Natl Acad Sci U S A 88: 6910-6915.
170. Seymour L, Bezwoda WR, Meyer K. 1990. Tumor factors predicting for prognosis in metastatic breast cancer. The presence of P24 predicts for response to treatment and duration of survival. Cancer 66: 2390-2394.
171. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM. 2003. 17-DMA-geldamycin is a novel water-soluble, orally bioavailable Hsp90 inhibitor with potent in vitro and in vivo anticancer activity. Proc AACR 44: 180 (A786).
172. Soldes OS, Kuick RD, Thompson IA, Hughes SJ, Orringer MB, Iannettoni MD, Hanash SM, Beer DG. 1999. Differential expression of Hsp27 in normal oesophagus, Barret's metaplasia and oesophageal adenocarcinomas. Br J Cancer 79: 595-603.
173. Solit DB, Anana M, Valentin G, et al. 2003. Phase I trial of 17-AAG (17-allylamino, 17-demethoxygeldanamycin) in patients (pts) with advanced cancer. Proc ASCO 22: 198 (A795).
174. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. 2003. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitises tumors to taxol. Cancer Res 63: 2139-2144.
175. Sorger PK, Pelham HRB. 1988. Yeast heat shock factor is an essential DNA-binding protein that exhibits temperature-dependent phosphorylation. Cell 54: 855-864.
176. Spears PA, Barnes JA. 2003. HSP70 enhances MCF-7 cell growth and estrogen receptor activity. Proc 1st Int Cong Stress Responses Biol Med Quebec, September 10-14. pp. 73.
177. Srivastava P. 2002. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20: 395-425.
178. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. 1998. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 8: 657-665.
179. Stammler G, Volm M. 1996. Expression of heat shock proteins, glutathione peroxidase and catalase in childhood acute lymphoblastic leukemia and nephroblastoma. Cancer Lett 99: 35-42.
180. Storm FK, Mahvi DM, Gilchrist KW. 1993. Hsp27 has no diagnostic or prognostic significance in prostate or bladder cancers. Urology 42: 379-382.
181. Strahler JR, Kuik R, Hanash SM. 1991. Diminished phosphorylation of a heat shock protein (HSP27) in infant acute lymphoblastic leukemia. Biochem Biophys Res Commun 175: 134-142.
182. Strik HM, Weller M, Frank B, Hermisson M, Deininger MH, Dichgans J, Meyermann R. 2000. Heat shock protein expression in human gliomas. Anticancer Res 20: 4457-4462.
183. Subjeck JR, Sciandra JJ, Johnson RJ. 1982. Heat shock proteins and thermotolerance: a comparison of induction kinetics. Br J Radiol 55: 579-584.
184. Syrigos KN, Harrington KJ, Karayiannakis AJ, Sekara E, Chatziyianni E, Syrigou EI, Waxman J. 2003. Clinical significance of heat shock protein-70 expression in bladder cancer. Urology 61: 677-680.
185. Takahashi S, Mikami T, Watanabe Y, et al. 1994. Correlation of heat shock protein 70 expression with estrogen receptor levels in invasive human breast cancer. Am J Clin Pathol 101: 519-525.
186. Takashi M, Katsuno S, Sakata T, Ohshima S, Kato K. 1998. Different concentrations of two small stress proteins, alphaB crystalline and HSP27 in human urological tumor tissues. Urol Res 26: 395-399.
187. Takeno S, Noguchi T, Kikuchi R, Sato T, Uchida Y, Yokoyama S. 2001a. Analysis of the survival period in respectable stage IV gastric cancer. Ann Surg Oncol 8: 215-221.
188. Takeno S, Noguchi T, Takahashi Y, Kikuchi R, Uchida Y, Yokoyama S. 2001b. Immunohistochemical and clinicopathologic analysis of response to neoadjuvant therapy for esophageal squamous cell carcinoma. Dis Esophagus 14: 149-154.
189. Tang D, Khaleque AA, Jones ER, Theriault JR, Li C, Wong WH, Stevenson MA, Calderwood SK. 2005. Expression of heat shock proteins and HSP messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. Cell Stress Chaperones 10: 46-59.
190. Tauchi K, Tsutsumi Y, Hori S, Yoshimura S, Osamura RY, Watanabe K. 1991. Expression of heat shock protein 70 and c-myc protein in human breast cancer: an immunohistochemical study. Jpn J Clin Oncol 21: 256-263.
191. Têtu B, Brisson J, Landry J, Huot J. 1995. Prognostic significance of heat-shock protein-27 in node-positive breast carcinoma: an immunohistochemical study. Breast Cancer Res Treat 36: 93-97.
192. Têtu B, Lacasse B, Bouchard HL, Lagacé R, Huot J, Landry J. 1992. Prognostic influence of HSP-27 expression in malignant fibrous histiocytoma: a clinicopathological and immunohistochemical study. Cancer Res 52: 2325-2328.
193. Thanner F, Sutterlin MW, Kapp M, Rieger L, Kristen P, Dietl J, Gassel AM, Muller T. 2003. Heat-shock protein 70 as a prognostic marker in node-negative breast cancer. Anticancer Res 23: 1057-1062.
194. Thor A, Benz C, Moore D, et al. 1991. Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J Natl Cancer Inst 83: 170-178.
195. Todryk SM, Gough MJ, Pockley AG. 2003. Facets of heat shock protein 70 show immunotherapeutic potential. Immunology 110: 1-9.
196. Townsend PA, Dublin E, Hart IR, et al. 2002. BAG-I expression in human breast cancer: interrelationships between BAG-1 RNA, protein, HSC70 expression and clinicopathological data. J Pathol 197: 51-59.
197. Trautinger F, Kindas-Mugge I, Dekrout B, Rnobler RM, Metze D. 1995. Expression of the 27-kDa heat shock protein in human epidermis and in epidermal neoplasms: an immunohistochemical study. Br J Dermatol 133: 194-202.
198. Trieb K, Gerth R, Holzer G, Grohs JG, Berger P, Kotz R. 2000a. Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy. Br J Cancer 82: 85-87.
199. Trieb K, Gerth R, Windhager R, Grohs JG, Holzer G, Berger P, Kotz R. 2000b. Serum antibodies against the heat shock protein 60 are elevated in patients with osteosarcoma. Immunobiology 201: 368-376.
200. Trieb K, Kohlbeck R, Lang S, Klinger H, Blahovec H, Kotz R. 2000c. Heat shock protein 72 expression in chondrosarcoma correlates with differentiation. J Cancer Res Clin Oncol 126: 667-670.
201. Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R, Dirnhofer S. 1998. Heat shock protein 72 expression in osteosarcomas correlated with good response to neoadjuvant chemotherapy. Human Pathol 29: 1050-1055.
202. Ungar DR, Hailat N, Strahler JR, Kuik RD, Brodeur GM, Seeger RC, Reynolds CP, Hanash SM. 1994. Hsp27 expression in neuroblastoma: correlation with disease stage. J Natl Cancer Inst 86: 780-784.
203. Uozaki H, Ishida T, Kakiuchi C, Horiuchi H, Gotoh T, Iijima T, Imamura T, Machinami R. 2000. Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol Res Pract 196: 665-673.
204. van de Vijver MJ, He YD, van't Veer LJ, et al. 2002. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 34: 1999-2009.
205. Vanmuylder N, Evrard L, Daelemans P, Van Reck J, Dourov N. 2000. Expression of heat shock proteins in salivary gland rumors. Immunohistochemical study of HSP27, HSP70, HSP90, and HSP110: a propos of 50 cases. Ann Pathol 20: 190-195.
206. van't Veer LJ, Dai H, van de Vijver MJ, et al. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
207. Vargas-Roig LM, Fanelli MA, Lopez LA, Gago FE, Tello O, Aznar JC, Ciocca DR. 1997. Heat shock proteins and cell proliferation in human breast cancer biopsy samples. Cancer Detect Prev 21: 41-451.
208. Vargas-Roig LM, Gago FE, Tello O, Aznar JC, Ciocca DR. 1998. Heat shock expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer (Pred Oncol) 79: 468-475.
209. Vargas Roig LM, Lotfi H, Olcese JE, Lo Castro G, Ciocca DR. 1993. Effect of short-term tamoxifen administration in patients with invasive cervical cancer. Anticancer Res 13: 2457-2464.
210. Vegh GL, Fulop V, Liu Y, et al. 1999. Differential gene expression pattern between normal human trophoblast and choriocarcinoma cell lines: downregulation of heat shock protein-27 in choriocarcinoma in vitro and in vivo. Gynecol Oncol 75: 391-396.
211. Vidal CI, Mintz PJ, Lu K, et al. 2004. An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene 23: 8859-8867.
212. Voellmy R. 1994. Transduction of the stress signal and mechanisms of transcriptional regulation of heat shock/stress protein expression in higher eukaryotes. Crit Rev Enkaryot Gene Expr 4: 357-401.
213. Voellmy R. 2004. On mechanisms that control heat shock transcription factor activity in metazoan cells. Cell Stress Chaperones 9: 122-133.
214. Volloch VZ, Sherman MY. 1999. Oncogenic potential of Hsp72. Oncogene 18: 3648-3651.
215. Volm M, Rittgen W. 2000. Cellular predictive factors for the drug response of lung cancer. Anticancer Res 20: 3449-3458.
216. Wang Q, An L, Chen Y, Yue S. 2002. Expression of endoplasmic reticulum molecular chaperone GRP94 in human lung cancer tissues and its clinical significance. Chin Med J (Engl) 115: 1615-1619.
217. Wang XY, Chen X, Manjili MH, Repasky EA, Henderson R, Subjeck JR. 2003a. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp110. Cancer Res 63: 2553-2560.
218. Wang XY, Kazim L, Repasky EA, Subjeck JR. 2003b. Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease. Int J Cancer 105: 226-231.
219. Wang Y, Theriault JR, He H, Gong J, Calderwood SK. 2004. Expression of a dominant negative heat shock factor-1 construct inhibits aneuploidy in prostate carcinoma cells. J Biol Chem 279: 32651-32659.
220. Wataba K, Saito T, Fukunaka K, Ashihara K, Nishimura M, Kudo R. 2001. Over-expression of heat shock proteins in carcinogenic endometrium. Int J Cancer 91: 448-456.
221. Watson RWG, Lebret T, Fitzpatrick JM. 2003. Heat shock proteins in the genitourinary system. Curr Urol Rep 4: 70-76.
222. Workman P. 2002. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone. Cancer Detect Prev 26: 405-410.
223. Wu C. 1995. Heat shock transcription factors: structure and regulation. Ann Rev Cell Dev Biol 11: 441-469.
224. Xia W, Hardy L, Liu L, Zhao S, Goodman M, Voellmy R, Spector NL. 2003. Concurrent exposure to heat shock and H7 synergizes to trigger breast cancer cell apoptosis while sparing normal cells. Breast Cancer Res Treat 77: 233-243.
225. Xiao K, Liu W, Qu S, Sun H, Tang J. 1996. Study of heat shock protein HSP90 alpha, HSP70, HSP27 mRNA expression in human acute leukaemia cells. J Tongji Med Univ 16: 212-216.
226. Yano M, Naito Z, Yokoyama M, Shiraki Y, Ishiwata T, Inokuchi M, Asano G. 1999. Expression of Hsp90 and cyclin D1 in human breast cancer. Cancer Lett 137: 45-51.
227. Yokota S, Yamamoto Y, Shimizu K, et al. 2001. Increased expression of cytosolic chaperonin CCT in human hepatocellular and colonic carcinoma. Cell Stress Chaperones 6: 345-350.
228. Yokoyama N, Iwaki T, Goldman JE, Tateishi J, Fukui M. 1993. Small heat-shock protein is expressed in meningiomas and in granulofilamentous inclusion bodies. Acta Neuropathol (Ben) 85: 248-255.
229. Zhao M, Tang D, Lechpammer S, Huffman A, Asea AA, Stevenson MA, Calderwood SK. 2002. Double stranded RNA-dependent protein kinase (pkr) is essential for thermotolerance, accumulation of HSP70 and stabilization of ARE containing HSP70 mRNA during stress. J Biol Chem 277: 44539-44547.
230. Zhong L, Peng X, Hidalgo GE, Doherty DE, Stromberg AJ, Hirschowitz EA. 2003. Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients. Cancer Detect Prev 27: 285-290.
231. Zlotta AR, Drowart A, Huygen K, et al. 1997. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guerin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol 109: 157-165.